Deferasirox
نویسندگان
چکیده
منابع مشابه
Deferasirox induced liver injury in haemochromatosis.
Durg-induced liver injury is a common side-effect of many medicines. It is particularly problem when the original condition under treatment is already causing liver damage. This report describes the hepatotoxicity induced by Deferasirox in a patient with haemochromatosis with a discussion of possible pathogenetic mechanism.
متن کاملDeferasirox in mucormycosis: hopefully, not defeated.
References 1 Li C, Kuti JL, Nightingale CH et al. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 2005; 56: 388–95. 2 Roberts JA, Norris R, Paterson DL et al. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol 2011; doi: 10.1111/ j.1365-2125.2011.04080.x. 3 Seyler S, Cotton...
متن کاملPharmacokinetics and Safety of Deferasirox in Subjects with Chronic Kidney Disease Undergoing Haemodialysis Running title: Deferasirox in chronic kidney disease
Aim: Treatment of chronic kidney disease (CKD) includes parenteral iron therapy, and these infusions can lead to iron overload. Secondary iron overload is typically treated with iron chelators, of which deferasirox is one of the most promising. However, it has not been studied in patients with CKD and iron overload. Methods: A pilot study was conducted to evaluate the pharmacokinetics and safet...
متن کاملDeferiprone or deferasirox for cardiac siderosis in beta-thalassemia major.
We read with interest the article by Pepe et al. wherein the authors retrospectively compared cardiac iron burden measured by T2* magnetic resonance imaging (MRI) in three groups of beta-thalassemia major patients treated with desferrioxamine, deferiprone, or deferasirox monotherapy for more than one year. The mean global heart T2* value was significantly higher in the deferiprone compared to t...
متن کاملDeferasirox pharmacokinetics in patients with adequate versus inadequate response.
Tens of thousands of transfusion-dependent (eg, thalassemia) patients worldwide suffer from chronic iron overload and its potentially fatal complications. The oral iron chelator deferasirox has become commercially available in many countries since 2006. Although this alternative to parenteral deferoxamine has been a major advance for patients with transfusional hemosiderosis, a proportion of pa...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Reactions Weekly
سال: 2021
ISSN: ['1179-2051', '0114-9954']
DOI: https://doi.org/10.1007/s40278-021-91599-3